$-0.17 EPS Expected for Endologix, Inc. (ELGX)

October 29, 2017 – By Adrian Mccoy

 $ 0.17 EPS Expected for Endologix, Inc. (ELGX)
Investors sentiment decreased to 0.82 in 2017 Q2. Its down 0.35, from 1.17 in 2017Q1. It fall, as 30 investors sold Endologix, Inc. shares while 31 reduced holdings. 16 funds opened positions while 34 raised stakes. 86.54 million shares or 7.40% less from 93.45 million shares in 2017Q1 were reported.
Legal General Group Public Ltd Com has 21,064 shares. Metropolitan Life has invested 0% in Endologix, Inc. (NASDAQ:ELGX). Art Advsr accumulated 161,791 shares. Deutsche Comml Bank Ag invested in 0% or 187,626 shares. Moreover, Bancshares Of New York Mellon has 0% invested in Endologix, Inc. (NASDAQ:ELGX). Clearbridge Invests Lc owns 14,138 shares or 0% of their US portfolio. Credit Suisse Ag accumulated 43,838 shares or 0% of the stock. Stephens Ar holds 0.14% of its portfolio in Endologix, Inc. (NASDAQ:ELGX) for 845,016 shares. Partner Investment Management L P invested in 99,736 shares or 0.65% of the stock. Moreover, Rhenman & Partners Asset Management has 1.1% invested in Endologix, Inc. (NASDAQ:ELGX) for 1.58 million shares. Villere St Denis J And Co Ltd Llc owns 15,000 shares or 0% of their US portfolio. Perkins Capital Mgmt Inc accumulated 10,100 shares. 321,309 were reported by Schwab Charles Inv Inc. C Gp Hldg A S has 0.04% invested in Endologix, Inc. (NASDAQ:ELGX). Bluecrest Capital Mgmt Limited holds 0% in Endologix, Inc. (NASDAQ:ELGX) or 17,626 shares.

Since May 19, 2017, it had 5 buys, and 0 insider sales for $329,126 activity. 5,000 shares valued at $22,200 were bought by Zenty III Thomas F on Monday, May 22. Mitchell Robert D bought 2,200 shares worth $9,504. $86,400 worth of Endologix, Inc. (NASDAQ:ELGX) was bought by NEELS GUIDO J on Friday, May 19. The insider Lemaitre Dan bought 22,522 shares worth $99,772.

Investors wait Endologix, Inc. (NASDAQ:ELGX) to report on November, 7. its quarterly earnings Wall Street analysts expect $-0.17 earnings per share, down $0.06 or 54.55 % from last year’s $-0.11 same quarter earnings. Endologix, Inc.’s Wall Street analysts see 70.00 % negative EPS growth, taking into account the $-0.10 EPS reproted in the previous quarter, The stock increased 3.99% or $0.2 on October 27, reaching $5.21. About 620,590 shares traded. Endologix, Inc. (NASDAQ:ELGX) has declined 63.00% since October 29, 2016 and is downtrending. It has underperformed by 79.70% the S&P500.

Endologix, Inc. (NASDAQ:ELGX) Ratings Coverage

Among 10 analysts covering Endologix Inc. (NASDAQ:ELGX), 3 have Buy rating, 0 Sell and 7 Hold. Therefore 30% are positive. Endologix Inc. had 40 analyst reports since August 4, 2015 according to SRatingsIntel. The firm has “Hold” rating by Oppenheimer given on Thursday, August 3. The rating was initiated by RBC Capital Markets with “Outperform” on Monday, October 19. The firm earned “Market Perform” rating on Tuesday, October 27 by BMO Capital Markets. The company was maintained on Monday, June 19 by BMO Capital Markets. The rating was initiated by Canaccord Genuity on Tuesday, October 27 with “Hold”. The rating was maintained by Canaccord Genuity with “Hold” on Thursday, August 17. Canaccord Genuity downgraded Endologix, Inc. (NASDAQ:ELGX) on Thursday, November 17 to “Hold” rating. BMO Capital Markets maintained Endologix, Inc. (NASDAQ:ELGX) rating on Friday, September 8. BMO Capital Markets has “Hold” rating and $5.0 target. The firm has “Hold” rating given on Wednesday, August 2 by Stifel Nicolaus. The stock of Endologix, Inc. (NASDAQ:ELGX) earned “Overweight” rating by JP Morgan on Thursday, August 6.

Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The company has market cap of $434.69 million. The Company’s products are intended for the treatment of abdominal aortic aneurysms . It currently has negative earnings. The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

More recent Endologix, Inc. (NASDAQ:ELGX) news were published by: Streetinsider.com which released: “Form 8-K ENDOLOGIX INC /DE/ For: Oct 06” on October 06, 2017. Also Streetinsider.com published the news titled: “Form 8-K ENDOLOGIX INC /DE/ For: Oct 19” on October 19, 2017. Businesswire.com‘s news article titled: “Endologix, Inc. to Announce Third Quarter 2017 Financial Results on November 7 …” with publication date: October 10, 2017 was also an interesting one.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.